Climb Bio Inc. Common Stock (CLYM)

About CLYM

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

28

Website

climbbio.com/

Fundamentals

1-day range

$14.38$15.12

Market cap

$676.28M

P/E (trailing)

—

P/E (forward)

-13.82

EPS (trailing)

$-0.78

Dividend yield

—

Beta

-0.01

Avg. volume

1.37M

Forecasts

14 analyst ratings

Climb Bio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CLYM

  Climb Bio Inc. Common Stock

  $14.56

  ▼ 3.32%
  Market cap $676.28MP/E —
  $1.54$18.33
• OCS

  Oculis Holding AG Ordinary shares

  $12.21

  ▼ 1.77%
  Market cap $689.43MP/E —
  $10.52$34.48
• CTMX

  CytomX Therapeutics Inc. Common Stock

  $3.22

  ▼ 5.99%
  Market cap $690.12MP/E —
  $1.9$8.21
• BBOT

  BridgeBio Oncology Therapeutics Inc. Common Stock

  $8.74

  ▼ 4.79%
  Market cap $660.88MP/E —
  $7$14.87
• DRUG

  Bright Minds Biosciences Inc. Common Stock

  $72.74

  ▼ 2.41%
  Market cap $723.93MP/E —
  $53.99$170
• MNPR

  Monopar Therapeutics Inc. Common Stock

  $112.17

  ▼ 1.55%
  Market cap $747.88MP/E —
  $32.04$124.82
• CRMD

  CorMedix Inc. Common Stock

  $8.31

  ▼ 0.06%
  Market cap $592.31MP/E 3.53
  $6.13$14.96

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $24
  benzinga · 8/24/2026
• HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $24
  Benzinga · 8/24/2026
• Wedbush Reiterates Outperform on Climb Bio, Maintains $20 Price Target
  Benzinga · 8/19/2026
• Truist Securities Maintains Buy on Climb Bio, Raises Price Target to $25
  Benzinga · 8/7/2026
• Climb Bio Q2 EPS $(0.18) Beats $(0.21) Estimate
  Benzinga · 8/6/2026

• Celebi Breanna Maurine · June 29, 2026 · Grant

  70.3K
• RA CAPITAL MANAGEMENT, L.P. · June 29, 2026 · Grant

  70.3K
• Levin Andrew David · June 5, 2026 · Grant

  40.0K
• Stephen Basil Thomas · June 5, 2026 · Grant

  40.0K
• Dunn Judith · June 5, 2026 · Grant

  40.0K
• Cumbo Alexander · June 5, 2026 · Grant

  40.0K
• Kimberlee C. Drapkin · June 5, 2026 · Grant

  40.0K
• RA Capital Healthcare Fund LP · June 5, 2026 · Grant

  40.0K
• WILLIAMS DOUGLAS E · June 5, 2026 · Grant

  40.0K
• RA Capital Healthcare Fund LP · April 29, 2026 · Grant

  2.11M @ $9.5

Institutional Ownership

March 31, 2026

Total shares held

32.21M

Total value held

$207.23M

Institutional holders

77